Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Context: Elevated total cholesterol (total‐C) and low‐density lipoprotein cholesterol (LDL‐C) levels are established risk factors for cardiovascular disease (CVD). HMG‐CoA reductase inhibitors (statins) are effective cholesterol‐lowering drugs that are commonly prescribed to treat this condition. These drugs are often combined with another class of drugs, fibric acid derivatives, to lower both cholesterol and triglyceride levels. Rhabdomyolysis is a known, rare serious side effect of statin monotherapy and of statin‐fibrate combination therapy. Objective: To examine Food and Drug Administration's (FDA's) postmarketing database for cases of rhabdomyolysis in relation to monotherapy and combination use and calculate reporting rates for this event. Design: Domestic cases of statin‐ and statin/gemfibrozil‐associated rhabdomyolysis were culled from FDA's database and reviewed. Rhabdomyolysis was defined by CPK ≥ 10 000 IU/L, myopathic signs and symptoms and clinical diagnosis of rhabdomyolysis. Reporting rates, consisting of number of reported cases/number of prescriptions for each drug, were then calculated to determine whether the reporting of rhabdomyolysis cases was commensurate with extent of use of each statin in the population. Setting: Cases were obtained from the FDA adverse event reporting system (AERS) database. Patients: NA. Main Outcome Measures: Number of rhabdomyolysis cases were evaluated, along with outcomes, such as renal failure, dialysis and death. Results: Of 866 total reported cases, 482 (56%) were associated with monotherapy and 384 (44%) related to combination therapy. More than 80% of reported cases for each drug resulted in hospitalization for renal failure and dialysis. 80 patients expired from events related directly to rhabdomyolysis. Reporting rates for all statins, except for cerivastatin, were similar and much lower than 1 per 100 000 prescriptions. The cerivastatin‐reporting rate was much higher at 4.24/100 000 prescriptions. Conclusions: Rhabdomyolysis is a rare, serious side effect of statin monotherapy and of statin‐fibrate combination therapy. Clinicians need to remain cognizant of this potential adverse event and discuss signs and symptoms of muscle toxicity with patients in order improve the benefits‐to‐risks of treating dyslipidemia with statins. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262 · cited 1×
“Coenzyme Q is a necessary transporter in the function of mitochondrial energy metabolism in muscle and it has been hypothesized that a reduction of coenzyme Q may lead to myopathy or rhabdomyolysis.(12,13) Because of the rarity of rhabdomyolysis, its incidence associated with statin therapy cannot be determined from e…”
BackgroundLaaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90266-x · Cited by 177 · cited 1×
“The exact mechanism for rhabdomyolysis induced by statins is not known, but these drugs have been speculated to lower levels of coenzyme Q (ubiquinone), though there are literature reports that suggest otherwise.(11) Table 2.”
Background
Cited by
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Huang, S., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
Wiviott, S. D., Cannon, C. P., Morrow, D. A., Ray, K. K., Pfeffer, M. A., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.064 · Cited by 340
Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 333
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
“Gemfibrozil, in particular, has been shown to increase exposure to and reduce the renal clearance of statins by inhibiting their glucuronidation,(83) potentially leading to severe side effects.(82) However, fenofibrate appears to be better tolerated than other fibrates, with no cases of rhabdomyolysis observed with fe…”
BackgroundEffect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
“Reports of myositis and myopathic symptoms increase with increased statin dose[5], with different classes of statins, when statins are coupled with other drugs[6], and with exercise[7, 8].”
BackgroundMyopathy with statin–fibrate combination therapy: clinical considerations
Jacobson, T. A. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.151 · Cited by 82
Metadata
- Authors
- Chang, J. T., Staffa, J. A., Parks, M., & Green, L.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2004-05-24
- Volume
- 13
- Issue
- 7
- Pages
- 417-426
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2102504779
- Cited by
- 152
- References
- 5
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.